DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans.

[1]  D. Weiner,et al.  DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees. , 1997, The Journal of infectious diseases.

[2]  D. Weiner,et al.  Nucleic acid immunization of chimpanzees as a prophylactic/immunotherapeutic vaccination model for HIV-1: prelude to a clinical trial. , 1997, Vaccine.

[3]  D. Weiner,et al.  Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination , 1997, Nature Medicine.

[4]  E. Karita,et al.  Primary infections with HIV-1 of women and their offspring in Rwanda: findings of heterogeneity at seroconversion, coinfection, and recombinants of HIV-1 subtypes A and C. , 1997, Virology.

[5]  V. Srikantan,et al.  Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation. , 1995, Virology.

[6]  R. Desrosiers.  Safety issues facing development of a live-attenuated, multiply deleted HIV-1 vaccine. , 1994, AIDS Research and Human Retroviruses.

[7]  V. Srikantan,et al.  DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates. , 1993, DNA and cell biology.

[8]  Bin Wang,et al.  Gene inoculation generates immune responses against human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Goedert,et al.  Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. , 1992, The Journal of clinical investigation.

[10]  J. Goedert,et al.  Vertical transmission of human immunodeficiency virus type 1: seroreactivity by maternal antibodies to the carboxy region of the gp41 envelope glycoprotein. , 1997, The Journal of infectious diseases.